Andrew Kaiser joined Miltenyi Biotec’s R&D in 2012, where he heads a team that focuses on developing tools and technologies for clinical applications of adoptive cell therapy and more specifically the automation of gene-modified T cell manufacturing. Elisa Manzotti, CEO of Cell and Gene Therapy Insights, talks with Andrew about the latest advances in the development of automated manufacturing solutions for the autologous cell therapies.